ID   CMT12
AC   CVCL_L329
AS   CVCL_X219
SY   CMT-12; Canine Mammary Tumor 12; CMT-2; CMT2; Canine Mammary Tumor-2
DR   GEO; GSM1974783
DR   Wikidata; Q54813839
RX   CelloPub=CLPUB00711;
RX   DOI=10.4236/ojvm.2012.24045;
RX   PubMed=3462415;
RX   PubMed=8476218;
RX   PubMed=11848473;
RX   PubMed=12529965;
RX   PubMed=19130492;
RX   PubMed=21801068;
RX   PubMed=21908323;
RX   PubMed=23238983;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=31175136;
CC   Part of: FACC canine tumor cell line panel.
CC   Doubling time: ~24 hours (PubMed=3462415); 19 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; VGNC:42490; KMT2C; Simple; p.Arg1201fs (c.3600delGinsAA); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; VGNC:47719; TP53; Simple; p.Val132Glu (c.395T>A); Zygosity=Homozygous (PubMed=31175136).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Caution: CMT-2 was renamed CMT-12 (PubMed=11848473).
CC   Caution: On the basis of the STR profile CMT12 and CMT27 seem to originate from the same donor (PubMed=21908323; PubMed=27197945).
CC   Derived from site: In situ; Mammary gland; UBERON=UBERON_0001911.
CC   Breed/subspecies: Poodle; VBO=VBO_0201048.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 235
ST   Dog FHC2054: 151,176
ST   Dog FHC2079: 271
ST   Dog PEZ1: 115
ST   Dog PEZ3: 113,119
ST   Dog PEZ5: 103
ST   Dog PEZ6: 176
ST   Dog PEZ8: 233,244
ST   Dog PEZ12: 277
ST   Dog PEZ20: 176
DI   NCIt; C124249; Canine mammary carcinoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
OI   CVCL_1R41 ! CMT27
SX   Female
AG   >10Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 10-04-25; Version: 22
//
RX   CelloPub=CLPUB00711;
RA   Sartin E.A.;
RT   "Biological properties of canine mammary tumors and cell lines.";
RL   Thesis PhD (1990); Auburn University College of Veterinary Medicine; Auburn; USA.
//
RX   DOI=10.4236/ojvm.2012.24045;
RA   Balkman C.E., Gieger T.L., Zgola M.M., Lewis L.D., McEntee M.C.;
RT   "In vitro characterization of docetaxel as a radiosensitizer in canine
RT   and feline cancer cell lines.";
RL   Open J. Vet. Med. 2:285-292(2012).
//
RX   PubMed=3462415; DOI=10.1093/jnci/77.3.783;
RA   Wolfe L.G., Smith B.B., Toivio-Kinnucan M.A., Sartin E.A.,
RA   Kwapien R.P., Henderson R.A., Barnes S.;
RT   "Biologic properties of cell lines derived from canine mammary
RT   carcinomas.";
RL   J. Natl. Cancer Inst. 77:783-792(1986).
//
RX   PubMed=8476218;
RA   Sartin E.A., Barnes S., Toivio-Kinnucan M.A., Wright J.C., Wolfe L.G.;
RT   "Heterogenic properties of clonal cell lines derived from canine
RT   mammary carcinomas and sensitivity to tamoxifen and doxorubicin.";
RL   Anticancer Res. 13:229-236(1993).
//
RX   PubMed=11848473;
RA   Vatne V., Litlekalsoey J., Thorsen F., Ness G.O., Wentzel-Larsen T.,
RA   Hostmark J.G.;
RT   "Characterization of cell lines originating from an invasive
RT   transitional cell carcinoma.";
RL   Anticancer Res. 21:3199-3207(2001).
//
RX   PubMed=12529965;
RA   Whitley E.M., Sellins K.S., Ewald S.J., Smith B.F., Yang S.-M.,
RA   Sartin E.A., Wolfe L.G.;
RT   "Canine mammary tumor cells transfected with B7-1 or B7-2 stimulate
RT   proliferation of peripheral blood mononuclear cells.";
RL   Anticancer Res. 22:2567-2574(2002).
//
RX   PubMed=19130492; DOI=10.1002/jcb.22034;
RA   DeInnocentes P., Agarwal P., Bird R.C.;
RT   "Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A
RT   defects in a spontaneous canine cell model of breast cancer.";
RL   J. Cell. Biochem. 106:491-505(2009).
//
RX   PubMed=21801068; DOI=10.2460/ajvr.72.8.1097;
RA   Stokol T., Daddona J.L., Mubayed L.S., Trimpert J., Kang S.;
RT   "Evaluation of tissue factor expression in canine tumor cells.";
RL   Am. J. Vet. Res. 72:1097-1106(2011).
//
RX   PubMed=21908323; DOI=10.1177/1040638711408064;
RA   O'Donoghue L.E., Rivest J.P., Duval D.L.;
RT   "Polymerase chain reaction-based species verification and
RT   microsatellite analysis for canine cell line validation.";
RL   J. Vet. Diagn. Invest. 23:780-785(2011).
//
RX   PubMed=23238983; DOI=10.1002/jcb.24476;
RA   Agarwal P., Sandey M., DeInnocentes P., Bird R.C.;
RT   "Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and
RT   out of the cell cycle in a spontaneous canine model of breast
RT   cancer.";
RL   J. Cell. Biochem. 114:1355-1363(2013).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:e0156689.1-e0156689.18(2016).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole-exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//